Efficacy response in CF patients treated with ivacaftor: Post-hoc analysis

Pediatric Pulmonology

Volumn 50, Issue 5, 2015, Pages 447-455

  Konstan, Michael W ^a   Plant, Barry J ^b   Elborn, J Stuart ^c   Rodriguez, Sally ^d   Munck, Anne ^e   Ahrens, Richard ^f   Johnson, Charles ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Department of Medicine National University of Ireland Cork   (Ireland)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d VERTEX PHARMACEUTICALS   (United States)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

CFTR; clinical response; cystic fibrosis; ivacaftor

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; PLACEBO; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY WEIGHT; CHILD; CHRONOTHERAPY; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS QUESTIONNAIRE REVISED; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL CONDITION IMPROVEMENT; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE OBSTRUCTION; NUMBERS NEEDED TO TREAT; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; POST HOC ANALYSIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE ASSESSMENT; RHINOPHARYNGITIS; SWEAT GLAND; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; DISEASE COURSE; GENETICS; LUNG FUNCTION TEST; MUTATION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SWEAT; WEIGHT GAIN;

ADOLESCENT; ADULT; AMINOPHENOLS; CHILD; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MUTATION; NUMBERS NEEDED TO TREAT; QUINOLONES; RESPIRATORY FUNCTION TESTS; SURVEYS AND QUESTIONNAIRES; SWEAT; WEIGHT GAIN; YOUNG ADULT;

EID: 84927911206     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23173     Document Type: Article

References (16)

1. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP, Jr., Urrutia A, Joubran J, Seepersaud S, Sussky K, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11: 237-245.
2. Ramsey BW, Boat TF,. Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr 1994; 124: 177-192.
3. Mayer-Hamblett N, Ramsey BW, Kronmal RA,. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007; 4: 370-377.
4. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
5. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013; 187: 1219-1225.
6. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B,. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127: 725-734.
7. 1 decline in patients with cystic fibrosis: a longitudinal study. Thorax 2012; 67: 860-866.
8. Barry PJ, Jones AM, Webb AK, Horsley AR,. Sweat chloride is not a useful marker of clinical response to Ivacaftor. Thorax 2014; 69: 586-587.
9. Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA,. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest 2013; 143: 14-18.
10. Seliger VI, Rodman D, Van Goor F, Schmelz A, Mueller P,. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation. J Cyst Fibros 2013; 12: 706-713.
11. Konstan MW, Butler SJ, Wohl MB, Stoddard M, Matousek R, Wagener JS, Johnson CA, Morgan WJ,. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003; 142: 624-630.
12. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151: 134-139.
13. 1 in adults with cystic fibrosis. J Cyst Fibros 2012; 11: 405-411.
14. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH,. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
15. Barry PJ, Plant BJ, Nair A, Bicknell S, Simmonds NJ, Bell NJ, Shafi NT, Daniels T, Shelmerdine S, Felton I, Gunaratnam C, Jones AM, Horsley AR,. Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. Chest 2014; 146: 152-158.
16. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW,. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Resp Crit Care Med 2014; 190: 175-184.